Moderna, Merck, and Pfizer-BioNTech are leading the charge with new vaccines for respiratory viruses in development.
Public attitudes toward vaccination have become increasingly complex in recent years. Factors such as vaccine fatigue and misinformation—which began circulating during the COVID-19 pandemic and has persisted—have eroded trust in vaccination, making some individuals hesitant to roll up their sleeves. Some who had previously relied on vaccine regimens began to question their value, increasing skepticism and causing a dip in vaccine uptake.
Amid these challenges, 2024 offers hope: Pharmaceutical research and development teams are pioneering new vaccines that leverage messenger RNA (mRNA) technology, expand protection to vulnerable populations, and streamline the vaccination process—efforts that may help mend ongoing divides. Here is a look at some of the most anticipated vaccine developments in 2024.
READ MORE: Immunization Resource Center
Exploring Challenges, Opportunities for Community Pharmacists in Tobacco Cessation
April 24th 2024By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.